Report Detail

Other Global Bladder Diseases Drug Market Growth (Status and Outlook) 2022-2028

  • RnM4494797
  • |
  • 04 November, 2022
  • |
  • Global
  • |
  • 124 Pages
  • |
  • LPI(LP Information)
  • |
  • Other

The global market for Bladder Diseases Drug is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

The APAC Bladder Diseases Drug market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The United States Bladder Diseases Drug market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The Europe Bladder Diseases Drug market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The China Bladder Diseases Drug market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

Global key Bladder Diseases Drug players cover Merck, Astellas Pharma Inc., Bristol-myers Squibb Company, Boston Scientific Corporation and Viatris Inc., etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

Report Coverage
This latest report provides a deep insight into the global Bladder Diseases Drug market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.

This report aims to provide a comprehensive picture of the global Bladder Diseases Drug market, with both quantitative and qualitative data, to help readers understand how the Bladder Diseases Drug market scenario changed across the globe during the pandemic and Russia-Ukraine War.

The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions.

Market Segmentation:
The study segments the Bladder Diseases Drug market and forecasts the market size by Type (Oral and Injection,), by Application (Overactive Bladder, Urinary Incontinence, Cystitis and Interstitial Cystitis), and region (APAC, Americas, Europe, and Middle East & Africa).

Segmentation by type
Oral
Injection

Segmentation by application
Overactive Bladder
Urinary Incontinence
Cystitis
Interstitial Cystitis
Bladder Cancer
Others

Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Major companies covered
Merck
Astellas Pharma Inc.
Bristol-myers Squibb Company
Boston Scientific Corporation
Viatris Inc.
Abbvie
Axonics, Inc.
Blue Wind Medical
Coloplast Corp.
Gaylord Chemical Company, Llc
Johnson & Johnson Services, Inc.
Kyorin Pharmaceutical Co., Ltd.
Laborie
Medtronic
Pfizer Inc.
Valencia Technologies
Sun Phamaceutical Industries Ltd.
Swati Spentose
Urovant Sciences
Zydus Group

Chapter Introduction
Chapter 1: Scope of Bladder Diseases Drug, Research Methodology, etc.
Chapter 2: Executive Summary, global Bladder Diseases Drug market size and CAGR, Bladder Diseases Drug market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Bladder Diseases Drug revenue, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Bladder Diseases Drug revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, revenue segment by country, by type, and application.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Bladder Diseases Drug market size forecast by region, by country, by type, and application
Chapter 13: Comprehensive company profiles of the leading players, including Merck, Astellas Pharma Inc., Bristol-myers Squibb Company, Boston Scientific Corporation, Viatris Inc., Abbvie, Axonics, Inc., Blue Wind Medical and Coloplast Corp., etc.
Chapter 14: Research Findings and Conclusion


1 Scope of the Report

  • 1.1 Market Introduction
  • 1.2 Years Considered
  • 1.3 Research Objectives
  • 1.4 Market Research Methodology
  • 1.5 Research Process and Data Source
  • 1.6 Economic Indicators
  • 1.7 Currency Considered

2 Executive Summary

  • 2.1 World Market Overview
    • 2.1.1 Global Bladder Diseases Drug Market Size 2017-2028
    • 2.1.2 Bladder Diseases Drug Market Size CAGR by Region 2017 VS 2022 VS 2028
  • 2.2 Bladder Diseases Drug Segment by Type
    • 2.2.1 Oral
    • 2.2.2 Injection
  • 2.3 Bladder Diseases Drug Market Size by Type
    • 2.3.1 Bladder Diseases Drug Market Size CAGR by Type (2017 VS 2022 VS 2028)
    • 2.3.2 Global Bladder Diseases Drug Market Size Market Share by Type (2017-2022)
  • 2.4 Bladder Diseases Drug Segment by Application
    • 2.4.1 Overactive Bladder
    • 2.4.2 Urinary Incontinence
    • 2.4.3 Cystitis
    • 2.4.4 Interstitial Cystitis
    • 2.4.5 Bladder Cancer
    • 2.4.6 Others
  • 2.5 Bladder Diseases Drug Market Size by Application
    • 2.5.1 Bladder Diseases Drug Market Size CAGR by Application (2017 VS 2022 VS 2028)
    • 2.5.2 Global Bladder Diseases Drug Market Size Market Share by Application (2017-2022)

3 Bladder Diseases Drug Market Size by Player

  • 3.1 Bladder Diseases Drug Market Size Market Share by Players
    • 3.1.1 Global Bladder Diseases Drug Revenue by Players (2020-2022)
    • 3.1.2 Global Bladder Diseases Drug Revenue Market Share by Players (2020-2022)
  • 3.2 Global Bladder Diseases Drug Key Players Head office and Products Offered
  • 3.3 Market Concentration Rate Analysis
    • 3.3.1 Competition Landscape Analysis
    • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
  • 3.4 New Products and Potential Entrants
  • 3.5 Mergers & Acquisitions, Expansion

4 Bladder Diseases Drug by Regions

  • 4.1 Bladder Diseases Drug Market Size by Regions (2017-2022)
  • 4.2 Americas Bladder Diseases Drug Market Size Growth (2017-2022)
  • 4.3 APAC Bladder Diseases Drug Market Size Growth (2017-2022)
  • 4.4 Europe Bladder Diseases Drug Market Size Growth (2017-2022)
  • 4.5 Middle East & Africa Bladder Diseases Drug Market Size Growth (2017-2022)

5 Americas

  • 5.1 Americas Bladder Diseases Drug Market Size by Country (2017-2022)
  • 5.2 Americas Bladder Diseases Drug Market Size by Type (2017-2022)
  • 5.3 Americas Bladder Diseases Drug Market Size by Application (2017-2022)
  • 5.4 United States
  • 5.5 Canada
  • 5.6 Mexico
  • 5.7 Brazil

6 APAC

  • 6.1 APAC Bladder Diseases Drug Market Size by Region (2017-2022)
  • 6.2 APAC Bladder Diseases Drug Market Size by Type (2017-2022)
  • 6.3 APAC Bladder Diseases Drug Market Size by Application (2017-2022)
  • 6.4 China
  • 6.5 Japan
  • 6.6 Korea
  • 6.7 Southeast Asia
  • 6.8 India
  • 6.9 Australia

7 Europe

  • 7.1 Europe Bladder Diseases Drug by Country (2017-2022)
  • 7.2 Europe Bladder Diseases Drug Market Size by Type (2017-2022)
  • 7.3 Europe Bladder Diseases Drug Market Size by Application (2017-2022)
  • 7.4 Germany
  • 7.5 France
  • 7.6 UK
  • 7.7 Italy
  • 7.8 Russia

8 Middle East & Africa

  • 8.1 Middle East & Africa Bladder Diseases Drug by Region (2017-2022)
  • 8.2 Middle East & Africa Bladder Diseases Drug Market Size by Type (2017-2022)
  • 8.3 Middle East & Africa Bladder Diseases Drug Market Size by Application (2017-2022)
  • 8.4 Egypt
  • 8.5 South Africa
  • 8.6 Israel
  • 8.7 Turkey
  • 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities
  • 9.2 Market Challenges & Risks
  • 9.3 Industry Trends

10 Global Bladder Diseases Drug Market Forecast

  • 10.1 Global Bladder Diseases Drug Forecast by Regions (2023-2028)
    • 10.1.1 Global Bladder Diseases Drug Forecast by Regions (2023-2028)
    • 10.1.2 Americas Bladder Diseases Drug Forecast
    • 10.1.3 APAC Bladder Diseases Drug Forecast
    • 10.1.4 Europe Bladder Diseases Drug Forecast
    • 10.1.5 Middle East & Africa Bladder Diseases Drug Forecast
  • 10.2 Americas Bladder Diseases Drug Forecast by Country (2023-2028)
    • 10.2.1 United States Bladder Diseases Drug Market Forecast
    • 10.2.2 Canada Bladder Diseases Drug Market Forecast
    • 10.2.3 Mexico Bladder Diseases Drug Market Forecast
    • 10.2.4 Brazil Bladder Diseases Drug Market Forecast
  • 10.3 APAC Bladder Diseases Drug Forecast by Region (2023-2028)
    • 10.3.1 China Bladder Diseases Drug Market Forecast
    • 10.3.2 Japan Bladder Diseases Drug Market Forecast
    • 10.3.3 Korea Bladder Diseases Drug Market Forecast
    • 10.3.4 Southeast Asia Bladder Diseases Drug Market Forecast
    • 10.3.5 India Bladder Diseases Drug Market Forecast
    • 10.3.6 Australia Bladder Diseases Drug Market Forecast
  • 10.4 Europe Bladder Diseases Drug Forecast by Country (2023-2028)
    • 10.4.1 Germany Bladder Diseases Drug Market Forecast
    • 10.4.2 France Bladder Diseases Drug Market Forecast
    • 10.4.3 UK Bladder Diseases Drug Market Forecast
    • 10.4.4 Italy Bladder Diseases Drug Market Forecast
    • 10.4.5 Russia Bladder Diseases Drug Market Forecast
  • 10.5 Middle East & Africa Bladder Diseases Drug Forecast by Region (2023-2028)
    • 10.5.1 Egypt Bladder Diseases Drug Market Forecast
    • 10.5.2 South Africa Bladder Diseases Drug Market Forecast
    • 10.5.3 Israel Bladder Diseases Drug Market Forecast
    • 10.5.4 Turkey Bladder Diseases Drug Market Forecast
    • 10.5.5 GCC Countries Bladder Diseases Drug Market Forecast
  • 10.6 Global Bladder Diseases Drug Forecast by Type (2023-2028)
  • 10.7 Global Bladder Diseases Drug Forecast by Application (2023-2028)

11 Key Players Analysis

  • 11.1 Merck
    • 11.1.1 Merck Company Information
    • 11.1.2 Merck Bladder Diseases Drug Product Offered
    • 11.1.3 Merck Bladder Diseases Drug Revenue, Gross Margin and Market Share (2020-2022)
    • 11.1.4 Merck Main Business Overview
    • 11.1.5 Merck Latest Developments
  • 11.2 Astellas Pharma Inc.
    • 11.2.1 Astellas Pharma Inc. Company Information
    • 11.2.2 Astellas Pharma Inc. Bladder Diseases Drug Product Offered
    • 11.2.3 Astellas Pharma Inc. Bladder Diseases Drug Revenue, Gross Margin and Market Share (2020-2022)
    • 11.2.4 Astellas Pharma Inc. Main Business Overview
    • 11.2.5 Astellas Pharma Inc. Latest Developments
  • 11.3 Bristol-myers Squibb Company
    • 11.3.1 Bristol-myers Squibb Company Company Information
    • 11.3.2 Bristol-myers Squibb Company Bladder Diseases Drug Product Offered
    • 11.3.3 Bristol-myers Squibb Company Bladder Diseases Drug Revenue, Gross Margin and Market Share (2020-2022)
    • 11.3.4 Bristol-myers Squibb Company Main Business Overview
    • 11.3.5 Bristol-myers Squibb Company Latest Developments
  • 11.4 Boston Scientific Corporation
    • 11.4.1 Boston Scientific Corporation Company Information
    • 11.4.2 Boston Scientific Corporation Bladder Diseases Drug Product Offered
    • 11.4.3 Boston Scientific Corporation Bladder Diseases Drug Revenue, Gross Margin and Market Share (2020-2022)
    • 11.4.4 Boston Scientific Corporation Main Business Overview
    • 11.4.5 Boston Scientific Corporation Latest Developments
  • 11.5 Viatris Inc.
    • 11.5.1 Viatris Inc. Company Information
    • 11.5.2 Viatris Inc. Bladder Diseases Drug Product Offered
    • 11.5.3 Viatris Inc. Bladder Diseases Drug Revenue, Gross Margin and Market Share (2020-2022)
    • 11.5.4 Viatris Inc. Main Business Overview
    • 11.5.5 Viatris Inc. Latest Developments
  • 11.6 Abbvie
    • 11.6.1 Abbvie Company Information
    • 11.6.2 Abbvie Bladder Diseases Drug Product Offered
    • 11.6.3 Abbvie Bladder Diseases Drug Revenue, Gross Margin and Market Share (2020-2022)
    • 11.6.4 Abbvie Main Business Overview
    • 11.6.5 Abbvie Latest Developments
  • 11.7 Axonics, Inc.
    • 11.7.1 Axonics, Inc. Company Information
    • 11.7.2 Axonics, Inc. Bladder Diseases Drug Product Offered
    • 11.7.3 Axonics, Inc. Bladder Diseases Drug Revenue, Gross Margin and Market Share (2020-2022)
    • 11.7.4 Axonics, Inc. Main Business Overview
    • 11.7.5 Axonics, Inc. Latest Developments
  • 11.8 Blue Wind Medical
    • 11.8.1 Blue Wind Medical Company Information
    • 11.8.2 Blue Wind Medical Bladder Diseases Drug Product Offered
    • 11.8.3 Blue Wind Medical Bladder Diseases Drug Revenue, Gross Margin and Market Share (2020-2022)
    • 11.8.4 Blue Wind Medical Main Business Overview
    • 11.8.5 Blue Wind Medical Latest Developments
  • 11.9 Coloplast Corp.
    • 11.9.1 Coloplast Corp. Company Information
    • 11.9.2 Coloplast Corp. Bladder Diseases Drug Product Offered
    • 11.9.3 Coloplast Corp. Bladder Diseases Drug Revenue, Gross Margin and Market Share (2020-2022)
    • 11.9.4 Coloplast Corp. Main Business Overview
    • 11.9.5 Coloplast Corp. Latest Developments
  • 11.10 Gaylord Chemical Company, Llc
    • 11.10.1 Gaylord Chemical Company, Llc Company Information
    • 11.10.2 Gaylord Chemical Company, Llc Bladder Diseases Drug Product Offered
    • 11.10.3 Gaylord Chemical Company, Llc Bladder Diseases Drug Revenue, Gross Margin and Market Share (2020-2022)
    • 11.10.4 Gaylord Chemical Company, Llc Main Business Overview
    • 11.10.5 Gaylord Chemical Company, Llc Latest Developments
  • 11.11 Johnson & Johnson Services, Inc.
    • 11.11.1 Johnson & Johnson Services, Inc. Company Information
    • 11.11.2 Johnson & Johnson Services, Inc. Bladder Diseases Drug Product Offered
    • 11.11.3 Johnson & Johnson Services, Inc. Bladder Diseases Drug Revenue, Gross Margin and Market Share (2020-2022)
    • 11.11.4 Johnson & Johnson Services, Inc. Main Business Overview
    • 11.11.5 Johnson & Johnson Services, Inc. Latest Developments
  • 11.12 Kyorin Pharmaceutical Co., Ltd.
    • 11.12.1 Kyorin Pharmaceutical Co., Ltd. Company Information
    • 11.12.2 Kyorin Pharmaceutical Co., Ltd. Bladder Diseases Drug Product Offered
    • 11.12.3 Kyorin Pharmaceutical Co., Ltd. Bladder Diseases Drug Revenue, Gross Margin and Market Share (2020-2022)
    • 11.12.4 Kyorin Pharmaceutical Co., Ltd. Main Business Overview
    • 11.12.5 Kyorin Pharmaceutical Co., Ltd. Latest Developments
  • 11.13 Laborie
    • 11.13.1 Laborie Company Information
    • 11.13.2 Laborie Bladder Diseases Drug Product Offered
    • 11.13.3 Laborie Bladder Diseases Drug Revenue, Gross Margin and Market Share (2020-2022)
    • 11.13.4 Laborie Main Business Overview
    • 11.13.5 Laborie Latest Developments
  • 11.14 Medtronic
    • 11.14.1 Medtronic Company Information
    • 11.14.2 Medtronic Bladder Diseases Drug Product Offered
    • 11.14.3 Medtronic Bladder Diseases Drug Revenue, Gross Margin and Market Share (2020-2022)
    • 11.14.4 Medtronic Main Business Overview
    • 11.14.5 Medtronic Latest Developments
  • 11.15 Pfizer Inc.
    • 11.15.1 Pfizer Inc. Company Information
    • 11.15.2 Pfizer Inc. Bladder Diseases Drug Product Offered
    • 11.15.3 Pfizer Inc. Bladder Diseases Drug Revenue, Gross Margin and Market Share (2020-2022)
    • 11.15.4 Pfizer Inc. Main Business Overview
    • 11.15.5 Pfizer Inc. Latest Developments
  • 11.16 Valencia Technologies
    • 11.16.1 Valencia Technologies Company Information
    • 11.16.2 Valencia Technologies Bladder Diseases Drug Product Offered
    • 11.16.3 Valencia Technologies Bladder Diseases Drug Revenue, Gross Margin and Market Share (2020-2022)
    • 11.16.4 Valencia Technologies Main Business Overview
    • 11.16.5 Valencia Technologies Latest Developments
  • 11.17 Sun Phamaceutical Industries Ltd.
    • 11.17.1 Sun Phamaceutical Industries Ltd. Company Information
    • 11.17.2 Sun Phamaceutical Industries Ltd. Bladder Diseases Drug Product Offered
    • 11.17.3 Sun Phamaceutical Industries Ltd. Bladder Diseases Drug Revenue, Gross Margin and Market Share (2020-2022)
    • 11.17.4 Sun Phamaceutical Industries Ltd. Main Business Overview
    • 11.17.5 Sun Phamaceutical Industries Ltd. Latest Developments
  • 11.18 Swati Spentose
    • 11.18.1 Swati Spentose Company Information
    • 11.18.2 Swati Spentose Bladder Diseases Drug Product Offered
    • 11.18.3 Swati Spentose Bladder Diseases Drug Revenue, Gross Margin and Market Share (2020-2022)
    • 11.18.4 Swati Spentose Main Business Overview
    • 11.18.5 Swati Spentose Latest Developments
  • 11.19 Urovant Sciences
    • 11.19.1 Urovant Sciences Company Information
    • 11.19.2 Urovant Sciences Bladder Diseases Drug Product Offered
    • 11.19.3 Urovant Sciences Bladder Diseases Drug Revenue, Gross Margin and Market Share (2020-2022)
    • 11.19.4 Urovant Sciences Main Business Overview
    • 11.19.5 Urovant Sciences Latest Developments
  • 11.20 Zydus Group
    • 11.20.1 Zydus Group Company Information
    • 11.20.2 Zydus Group Bladder Diseases Drug Product Offered
    • 11.20.3 Zydus Group Bladder Diseases Drug Revenue, Gross Margin and Market Share (2020-2022)
    • 11.20.4 Zydus Group Main Business Overview
    • 11.20.5 Zydus Group Latest Developments

12 Research Findings and Conclusion

Summary:
Get latest Market Research Reports on Bladder Diseases Drug. Industry analysis & Market Report on Bladder Diseases Drug is a syndicated market report, published as Global Bladder Diseases Drug Market Growth (Status and Outlook) 2022-2028. It is complete Research Study and Industry Analysis of Bladder Diseases Drug market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

Last updated on

REPORT YOU MIGHT BE INTERESTED

Purchase this Report

$3,660.00
$7,320.00
3,056.10
6,112.20
3,539.22
7,078.44
506,836.80
1,013,673.60
298,473.00
596,946.00
Credit card Logo

Related Reports


Reason to Buy

Request for Sample of this report